Journal
BIOPHYSICAL CHEMISTRY
Volume 302, Issue -, Pages -Publisher
ELSEVIER
DOI: 10.1016/j.bpc.2023.107109
Keywords
Benzene sulfonamide derivative; Viral capsid; Coxsackievirus; Molecular dynamics simulations; Density functional theory
Ask authors/readers for more resources
This study reported the inhibitory activity of a benzene sulfonamide derivative against Coxsackievirus B3. By using molecular dynamics simulations and density functional theory, the key interactions between the compound and the viral capsid were investigated, and the differences in inhibitory activity against different mutants were explained. These findings are important for the development of drugs against CVB3.
Coxsackievirus B3 (CVB3), a serotype of enterovirus B, causes hand, foot, and mouth disease; pericarditis; and myocarditis. A benzene sulfonamide derivative is reported to have inhibitory activity against wild-type (WT) and eight mutants of the viral capsid of CVB3. Furthermore, the crystal structure of the complex formed between WT viral capsid of CVB3 and the derivative revealed binding at a novel druggable interprotomer pocket. We investigated how the compound could be a potent inhibitor of both WT and some mutants of CVB3 by determining binding to the viral capsid and the interaction energy with the binding pocket based on molecular dynamics simulations and density functional theory. We found that hydrogen bonds, pi-pi interactions, and electrostatic interactions are the key interactions with a protomer unit of CVB3 viral capsid. The residual interaction energy determined using density functional theory revealed key binding with VP1:Arg234 and a residue in the nearby VP1 unit (VP1':Arg219). These results explain why the compound is still a potent inhibitor against eight mutants. Moreover, the decreased inhibitory activity for some mutants could be explained by the calculated binding energy and the highest occupied molecular orbital and lowest unoccupied molecular orbital energy. The results will be helpful for the development of drugs resistant to CVB3.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available